Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.66 |
| ▸ | FNTA | P49354 | 6/20 | 0.54 |
| ▸ | FNTB | P49356 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768047 | 1.00 | TACR1 (0.66) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL7582580 | 1.00 | TACR1 (0.66) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8545840 | 0.91 | TACR1 (0.67) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8956909 | 0.91 | TACR1 (0.67) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8548669 | 0.87 | TACR1 (0.64) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8956927 | 0.87 | TACR1 (0.64) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8956845 | 0.86 | TACR1 (0.68) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8957044 | 0.86 | TACR1 (0.68) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8957083 | 0.86 | TACR1 (0.68) | TACR1FNTAFNTBMEN1KMT2A | |
| SCHEMBL8956821 | 0.84 | TACR1 (0.61) | TACR1FNTAFNTBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | claimed |
| EP-0912174-B1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH NON-PEPTIDAL NEURIKININ-1 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2004-04-28 | — | — | EP | claimed |
| US-20030215456-A1 | Method of treating cancer | YAO SUI-LONG (US) | 2003-11-20 | — | — | US | claimed |
| US-6525073-B2 | For achieving circadian rhythm phase-shifting effect in mammal | MERCK & CO. INC. | 2003-02-25 | — | — | US | claimed |
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MERCK & CO., INC. | 2002-03-21 | — | — | US | claimed |
| US-6329401-B1 | PREVENTION OR TREATMENT OF SLEEP DISORDER; BY ADMINISTERING A CNS PENETRATING NEUROKININ-1 RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2001-12-11 | — | — | US | claimed |
| US-6274604-B1 | ADMINISTERING A NEUROKININ-1 RECEPTOR ANTAGONIST TO ACHIEVE A CIRCADIAN RYTHM PHASE-SHIFTING TO IMPROVE THE QUALITY OF SLEEP | MERCK & CO., INC. | 2001-08-14 | — | — | US | claimed |
| US-6242446-B1 | Method for treating attention deficit disorder | MERCK & CO., INC. | 2001-06-05 | — | — | US | claimed |
| EP-0912174-A4 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | MERCK & CO INC (US) | 2000-12-06 | — | — | EP | claimed |
| JP-2000514455-A | — | — | 2000-10-31 | — | — | JP | claimed |
| US-6034105-A | NEUROKININ RECEPTOR ANTAGONIST; SLEEP DISORDERS | MERCK & CO., INC. (US) | 2000-03-07 | — | — | US | claimed |
| EP-0912174-A1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | claimed |
| WO-1998002158-A1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | MERCK & CO., INC. (US) | 1998-01-22 | — | — | WO | claimed |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | disclosed |
| EP-0912174-B1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH NON-PEPTIDAL NEURIKININ-1 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030215456-A1 | Method of treating cancer | YAO SUI-LONG (US) | 2003-11-20 | — | — | US | disclosed |
| US-5981526-A | SYNERGISTIC TREATMENT OR PREVENTION OF MIGRAINE | MERCK SHARP & DOHME LTD. (GB) | 1999-11-09 | — | — | US | disclosed |
| US-5972938-A | ADMINISTERING A TACHYKININ RECEPTOR ANTAGONIST TO TREAT OR PREVENT PSYCHOIMMUNOLOGIC DISORDER WHERE THE ORIGIN OR PROGRESSION IS CONTRIBUTED TO DIRECTLY OR INDIRECTLY BY PSYCHOLOGICAL STIMULI | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0912174-A1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002158-A1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | MERCK & CO., INC. (US) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MTNR1A, PROKR1, NTSR2 | TACR1 45/4885FNTA 4439/4885FNTB 4505/4885 |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | PTGS1, PTGS2, PTGES2 | TACR1 34/4885FNTA 4136/4885FNTB 4654/4885 |
| US-20030215456-A1 | Method of treating cancer | TACR1, TACR2, KLK3 | TACR1 1/4885FNTA 2302/4885FNTB 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.